{"product_id":"global-computational-biology-market-size-trends-growth-opportunity-by-service-in-house-and-contract-by-application-human-body-simulation-software-preclinical-drug-development-cellular-biological-simulation-clinical-trials-and-drug-discovery","title":"Global Computational Biology Market Size, Trends \u0026 Growth Opportunity, By Service (In-House, and Contract), By Application (Human Body Simulation Software, Preclinical Drug Development, Cellular \u0026 Biological Simulation, Clinical Trials, and Drug Discovery","description":"\u003cp\u003eGlobal Computational Biology Market Size, Trends and Growth Opportunity, by Application (Cellular \u0026amp; Biological Simulation, Drug Discovery \u0026amp; Disease Modelling, Preclinical Drug Development, Clinical Trials, Human Body Simulation Software), by Services (In-house, Contract), by End Use (Academics \u0026amp; Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2022-2027.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Computational Biology Market\u003c\/p\u003e \n\n\u003cp\u003eGlobal Computational Biology Market was valued at USD 4.12 million in 2022 and is slated to reach at USD 12.94 million by 2027 at a CAGR of 21.84% from 2022-2027.\u003c\/p\u003e\n\n\u003cp\u003eComputational biology referred as development and application of data analytical and theoretical methods, computational simulation, and mathematical modeling techniques which are used for study of biological systems. This is multifaceted field and that combines the principles of applied animation, computer science, anatomy, biophysics, biochemistry, ecology, and genomics. Also, computational biology includes bioinformatics and the science of using biological data to develop algorithms to understand biological systems and its relationships.\u003c\/p\u003e\n\n\u003cp\u003eMarket Drivers\u003c\/p\u003e\n\n\u003cp\u003eIncrease in number of clinical studies and in pharmacokinetics and pharmacogenomics for new drug discovery and development is considered as key driving factor which is expected to boost the global computational biology market growth. Furthermore, increase in demand for predictive models and funding from governments and private enterprises for research and development activities will positively contribute the market growth. Moreover, increase in use of computational tools in epi-genomics, genomics, proteomics, and meta genomics to understand 3D protein structural analysis, gene sequencing coupled with research activities in new drug designing process which expected to drive the market growth.\u003c\/p\u003e \n\n\u003cp\u003eMarket Restraints\u003c\/p\u003e\n\n\u003cp\u003eHowever, lack of trained professionals is the major restraining factor which is expected to hinder the global computational biology market growth.\u003c\/p\u003e\n\n\u003cp\u003eImpact of COVID-19\u003c\/p\u003e\n\n\u003cp\u003eThe market for computational biology has been impacted by the COVID-19 epidemic. Governments all across the world have imposed severe restrictions, including border locks, lockdowns, and stringent social segregation measures, to stop the spread of COVID-19. These actions had a big effect on the world economy, affecting many different industries. Governments from all around the world are collaborating with pharmaceutical and biotech businesses to combat the COVID-19 outbreak, from fostering the creation of vaccinations to preparing for issues with the distribution of medical supplies.\u003c\/p\u003e\n\n\u003cp\u003eRecent development\u003c\/p\u003e\n\n\u003cp\u003eApril 2022- 30 newly hired employees, including six newly hired employees based in India and one newly hired employee based in Japan, received non-statutory stock options to purchase a total of 101,715 shares of the company's common stock, according to a press release from Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is revolutionising the way therapeutics and materials are discovered.\u003c\/p\u003e\n\n\u003cp\u003eAjinomoto, a global supplier of cell culture media and development and manufacturing services (CDMO) to the biopharmaceutical industry, has implemented Genedata Bioprocess® to digitalize and automate their R\u0026amp;D and manufacturing operations in Japan and Korea, according to Genedata, the leading provider of enterprise software solutions for the biopharmaceutical research and development industry.\u003c\/p\u003e\n\n\u003cp\u003eMarket segmentation\u003c\/p\u003e\n\n\u003cp\u003eGlobal Computational Biology Market is segmented into services such as In-House, and Contract, by application such as Human Body Simulation Software, Preclinical Drug Development, Cellular \u0026amp; Biological Simulation, Clinical Trials, and Drug Discovery \u0026amp; Disease Modeling. Further, market is segmented into end user such as Academics, and Commercial.\u003c\/p\u003e\n\n\u003cp\u003eRegional Analysis\u003c\/p\u003e\n\n\u003cp\u003eAlso, Global Computational Biology Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East \u0026amp; Africa.\u003c\/p\u003e\n\n\u003cp\u003eMarket key Players\u003c\/p\u003e\n\n\u003cp\u003eVarious key players are discussed in this report such as Genedata AG, Chemical Computing Group Inc., Nimbus Discovery Plc., Simulation Plus Inc, Dassault Systems, Compugen Ltd., Insilico Biotechnology AG, and Leadscope Inc.\u003c\/p\u003e\n\n\u003cp\u003eMarket Taxonomy\u003c\/p\u003e\n\n\u003cp\u003eBy Service In-House ContractBy Application Human Body Simulation Software Preclinical Drug Development Cellular \u0026amp; Biological Simulation Clinical Trials Drug Discovery \u0026amp; Disease ModelingBy End User Academics CommercialBy Region North America Latin America Europe Asia Pacific Middle East \u0026amp; Africa\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 121 Pages \/ MCW16227559","offer_id":47645973643570,"sku":null,"price":4740.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-computational-biology-market-size-trends-growth-opportunity-by-service-in-house-and-contract-by-application-human-body-simulation-software-preclinical-drug-development-cellular-biological-simulation-clinical-trials-and-drug-discovery","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}